Cytosorbents (CTSO) Total Liabilities (2010 - 2026)

Cytosorbents (CTSO) has reported Total Liabilities for 17 consecutive years, with $38.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 6.34% year-over-year to $38.7 million; the trailing twelve-month figure through Jun 2026 stood at $38.7 million (up 6.34% YoY), and the FY2025 full-year result was $38.3 million, up 5.55% from the prior year.
• Total Liabilities climbed to $38.7 million in Q2 2026 per CTSO's latest filing, from $38.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $38.7 million in Q2 2026 and bottomed at $23.1 million in Q3 2022.
• Historically, Total Liabilities has averaged $32.0 million across 5 years, with a median of $32.1 million in 2023.
• The widest YoY moves for Total Liabilities: up 172.44% in 2022, down 5.43% in 2022.
• Over 5 years, Total Liabilities stood at $27.9 million in 2022, then climbed by 5.81% to $29.5 million in 2023, then grew by 23.04% to $36.3 million in 2024, then advanced by 5.55% to $38.3 million in 2025, then grew by 1.13% to $38.7 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $38.7 million, $38.4 million, and $38.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.